Clinical trials: Hypertrophy, Left Ventricular
Chronic Kidney Diseases, Hypertension
Remote Ischaemic Conditioning on Blood Pressure Control in Chronic Kidney Disease Patients
Chronic kidney disease (CKD) is one of the leading causes of death and disability in Singapore and worldwide. Hypertension is commonly inadequately controlled in patients with CKD and this is associated with CKD progression and…
- Conditions
- Chronic Kidney Diseases, Hypertension, Cardiovascular Diseases
- Trial name
- ERIC-BP-CKD (NCT03236350)
- Testing
- Active autoRIC® (CRIC Treatment)
- Where
- Singapore
- Volunteers
- 85 people
- Sponsor
- Singapore General Hospital
Cardiomyopathies
Analysis of Cardiac Biomarkers, ECG and CPET Results in Children With Cardiomyopathies
The aim of the study is to analyze cardiac biomarkers, electrocardiograms and cardio-pulmonary exercise test (CPET) results in children with cardiomyopathies.
- Trial name
- NCT04316923
- Testing
- ECG, 24-hour ECG monitoring, Cardio-pulmonary exercise test (CPET)
- Where
- Poland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Katarzyna Łuczak-Woźniak
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
- Trial name
- SEQUOIA-HCM (NCT05186818)
- Testing
- Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
- Where
- 114 sites in United States, China and 12 more
- Volunteers
- 282 people
- Sponsor
- Cytokinetics
Embolic Stroke of Undetermined Source
Cardea SOLOTM for Paroxysmal Atrial Fibrillation Diagnosis in ESUS Patients With Left Atrial Enlargement
The aim of the study is to evaluate the efficacy and safety of the Cardea SOLO Compared to 12 lead EKG for Paroxysmal Atrial Fibrillation Diagnosis in ESUS patients with Left Atrial Enlargement.
- Trial name
- NCT05431972
- Testing
- Cardea SOLO, 12 Lead EKG
- Where
- South Korea
- Volunteers
- 257 people
- Sponsor
- Asan Medical Center
Heart Failure, Heart Dilation
The Use of Blood Biochemical Markers for Diagnostics of Heart Muscle Diseases
The aim of the study is to determine the analytical characteristics of the microRNA enzymatic immunoassay (miREIA) method and to determine various relations among miRNA biomarkers and heart failure (HF) with reduced ejection…
- Conditions
- Heart Failure, Heart Dilation, Left Ventricular Hypertrophy
- Trial name
- NCT05726695
- Testing
- microRNA test, Heart ultrasound examination
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- University Hospital Ostrava
Aortic Valve Stenosis, Heart Failure
Left Atrial Volume Index in Asymptomatic Aortic Stenosis
Aortic stenosis results in increased filling pressures of the heart. Size and function of the left atrium may be a marker for more advanced heart disease (heart failure) in patients with severe aortic stenosis, not presenting any…
- Trial name
- LAVIAS (NCT02395107)
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Odense University Hospital
Disorders Associated With Peritoneal Dialysis
Assessment of Bioimpedance and Vitamin D and LV Mass in PD Patients (FLUID Study)
The main purpose of this study is to compare the effects of using bio-impedance analysis to guide management of fluid status versus routine clinical care on heart structure.
- Trial name
- FLUID (NCT01045980)
- Testing
- Bioimpedance and Vitamin D, Usual care and Vitamin D
- Where
- 2 sites in Canada
- Volunteers
- 74 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Ventricular Ejection Fraction, LVF
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF)…
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
- Trial name
- EFACT (NCT06699056)
- Testing
- 15-minutes of sitting during COR ECG Acquistion
- Where
- 8 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Hypertrophic Cardiomyopathy
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).
- Trial name
- PIONEER-OLE (NCT03496168)
- Testing
- mavacamten
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy (HCM), Left Ventricular Hypertrophy
AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic…
- Trial name
- NCT07263204
- Where
- China
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Coarctation of Aorta, Aortic Stenosis
Cardiac Remodeling and Circulating Biomarkers in Pediatric Left Ventricular Pressure Loading Lesions
This study is designed to learn more about children who have blockage of the left side of their heart. The goal is to determine how much the heart muscle has thickened before surgery and how it changes in the months after…
- Conditions
- Coarctation of Aorta, Aortic Stenosis, Cardiac Hypertrophy
- Trial name
- LVOTO (NCT02545790)
- Testing
- Echocardiogram, Serology
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Colorado, Denver
Healthy
Japan Central Aortic Pressure Prospective Study
Purpose of the study 1. The predictive value of central aortic pressure and aortic pulse wave velocity (PWV) in a Japanese population is not known.
- Trial name
- J-CARP (NCT01243840)
- Where
- Japan
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Yoshio Matsui
Left Ventricular Hypertrophy, Hypertension
Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis
Background: Angiotensin-converting-enzyme (ACE) inhibitors have a specific cardioprotective effect and, compared to treatment not directly interfering with the renin-angiotensin-system (RAS), significantly reduce cardiovascular…
- Trial name
- ARCADIA (NCT00985322)
- Testing
- ACE inhibitor Ramipril, non-RAS inhibitor antihypertensive therapy
- Where
- 29 sites in Italy
- Volunteers
- 269 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Hypertension, Left Ventricular Hypertrophy
Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy
The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular hypertrophy.
- Trial name
- NCT01425411
- Testing
- valsartan
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people
- Sponsor
- Mustafa Kemal University
Hypertension, Hypertrophy, Left Ventricular
The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal study in patients with left ventricular hypertrophy.
- Trial name
- NCT00045994
- Testing
- ALT-711
- Volunteers
- 180 people
- Sponsor
- Synvista Therapeutics, Inc
Chronic Kidney Disease, Left Ventricular Hypertrophy
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48 weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular hypertrophy (LVH).
- Trial name
- PRIMO (NCT00497146)
- Testing
- paricalcitol
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 227 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Cardiovascular Diseases, Carotid Intimal Media Thickness
Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.
Cardiovascular disease (CVD) is the major risk factor for death in end stage renal diseases (ESRD). Approximately 80% of ESRD patients have some degrees of left ventricular abnormalities at initiation of dialysis.
- Conditions
- Cardiovascular Diseases, Carotid Intimal Media Thickness, Left Ventricular Hypertrophy, Mean Platelet Volume
- Trial name
- NCT03759002
- Testing
- Imaging, Blood sampling
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Hypertrophic Cardiomyopathy
Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?
Aims and objectives: The primary objective of this study is to assess whether a structured exercise program improves cardiac relaxing properties in patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- WEDGE-HCM (NCT03537183)
- Testing
- Exercise training
- Where
- Denmark
- Volunteers
- 61 people
- Sponsor
- Bispebjerg Hospital
Hypertrophic Obstructive Cardiomyopathy
Speckle Tracking Echocardiography Analysis of Left Ventricular Myocardium After Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy
Objective to investigate the left ventricular (LV) systolic function by speckle tracking echocardiography before and after percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy…
- Trial name
- NCT04777188
- Testing
- Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Xijing Hospital
Hypertension,Essential, Obstructive Sleep Apnea
Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy
Obstructive sleep apnea syndrome (OSA) is the most frequent sleep disorder characterized by excessive decrease in muscle tone of the soft palate, the tongue and the posterior pharyngeal wall. It leads to airway collapse.
- Conditions
- Hypertension,Essential, Obstructive Sleep Apnea, Left Ventricular Hypertrophy
- Trial name
- NCT03186742
- Testing
- Eplerenone 50 mg Tab
- Volunteers
- 125 people
- Sponsor
- Poznan University of Medical Sciences